Skip to Content

Brinker Capital Investments LLC sells Mesa Laboratories, Inc. (NASDAQ:MLAB) stock.

Brinker Capital Investments LLC sells Mesa Laboratories, Inc. (NASDAQ:MLAB) stock.

The most recent disclosure that Brinker Capital Investments LLC made to the Securities and Exchange Commission revealed that during the third quarter, the company’s holdings in Mesa Laboratories, Inc. (NASDAQ: MLAB) were reduced by 18.0%. (SEC). The corporation had a total of 2,515 shares of stock in the medical equipment supplier after selling 551 shares during the period above. The most recent document that Brinker Capital Investments LLC presented to the SEC indicated that the company possessed a stake in Mesa Laboratories valued at $354,000.

A number of the company’s other institutional investors have made changes in the past few years to the proportion of the company’s stock they own.

Principal Financial Group Inc.

Increased its holdings in Mesa Laboratories by 13.8% during the second quarter by purchasing additional company shares. Following acquiring an additional 15,580 shares during the preceding quarter, Principal Financial Group Inc. now has 128,332 shares of the medical instruments supplier’s stock. These shares have a current value of $26,172,000.

Eagle Asset Management Inc.

Increased the proportion of Mesa Laboratories stock owned by 18.9% during the second quarter of the fiscal year.

Eagle Asset Management Inc. has increased the value of its holdings to $15,433,000 by purchasing an additional 12,039 shares of the medical instruments supplier’s stock since the beginning of this quarter. This brings the total value of Eagle Asset Management Inc.’s holdings to $15,433,000.

During the second quarter, the State of New Jersey Common Pension Fund D provided Mesa Laboratories with an investment of $2,185,000.

Mesa Laboratories was the recipient of this investment.

During the second quarter of this year, SG Americas Securities LLC invested $2,159,00 in Mesa Laboratories.

Mesa Laboratories was the recipient of this investment.

During the second quarter, Millennium Management LLC increased the proportion of Mesa Laboratories owned by 64.8%. This brings us to our last point.

Millennium Management LLC now holds 17,412 shares of the medical equipment supplier’s stock, valued at $3,551,000, after purchasing an additional 6,845 shares during the period in question.

At this time, hedge funds and other institutional investors control 93% of the company’s outstanding shares, making them the most significant shareholders.
On Thursday, trading on the NASDAQ MLAB began for $187.51 per share.

During the past year, Mesa Laboratories, Inc.

Experienced both its all-time low of $114.21 and its all-time high of $293.87.

Experienced both its all-time low of $114.21 and its all-time high of $293.87. The debt-to-equity ratio is 0.53, and the quick, current, and current ratios are 2.80. The debt-to-equity ratio is an important measure of financial health. The debt-to-equity ratio is essential to a company’s overall financial health. The business’s total value is $1 billion, based on its beta of 0.68 and its price-earnings ratio of -246.72.

According to the simple moving average of the last 200 trading days, the stock price is currently $170.40, and the simple moving average of the last 50 trading days is currently $176.06.

On November 3rd, 2018, Mesa Laboratories, Inc., which trades under the symbol “MLAB” on the NASDAQ, presented its most recent quarterly results report. The medical equipment manufacturer reported $2.07 per share earnings for the quarter, which was $1.24 more than the consensus estimate of $0.83 per share among industry experts. The company’s revenue for the quarter was $2.07 billion.

Mesa Laboratories had a return on equity that was profitable by 6.71 percentage points but a net margin that was unprofitable by 1.78 percentage points. The revenue for the company’s most recent quarter came in at a total of $58.75 million, which is significantly higher than the expected average of $53.24 million.

Analysts who work for businesses that offer their wares directly to end users projected that Mesa Laboratories, Inc. would post profits per share of $6.52 for the current financial year.

Recent news from the company also includes the declaration of a quarterly dividend, which is scheduled to be paid out on March 15th. Shareholders whose ownership was recorded as of the 28th of February will be eligible to receive a $0.16 dividend payment. When calculated on an annualized basis, this results in a dividend payment of $0.64 per share and a dividend yield of 0.34%. The 27th of February is the day that will decide whether or not a dividend will be withheld, so mark your calendars for that! (a Monday). The dividend payout ratio (DPR) for Mesa Laboratories is currently at -84.21 percent.

According to reports from other Mesa Laboratories news outlets, Chief Financial Officer John Sakys sold 2,100 shares of the company’s stock on Monday, January 23. This information was made public.

It was established that the shares were sold at an average price of $210.19 per share, which resulted in a total sale volume of 441,399.00 dollars. The chief financial officer currently holds a stake in the company equal to 9,696 shares, which have a value of $2,038,002.24 at the current market price. This page contains the filing containing the information about the transaction provided to the Securities and Exchange Commission (SEC). You can access the filing by clicking here.

According to reports from other Mesa Laboratories news outlets, Chief Financial Officer John Sakys sold 2,100 shares of the company’s stock on Monday, January 23. This information was made public.

It was established that the shares were sold at an average price of $210.19 per share, which resulted in a total sale volume of 441,399.00 dollars. The chief financial officer currently holds a stake in the company equal to 9,696 shares, which have a value of $2,038,002.24 at the current market price. This page contains the filing containing the information about the transaction provided to the Securities and Exchange Commission (SEC). You can access the filing by clicking here. Shannon Hall, also a company director, sold 230 shares of the firm’s stock on Thursday, the 8th of December. The shares were bought and sold for $40,243.10, totaling $174.97 for each share throughout the transaction. The director now has 957 shares of the company, which have a combined value of $167,446.29, as a direct result of the transaction that took place earlier.

Disclosures that are related to the sale might be found in this section of the website. Corporate insiders have sold 6,401 shares of company stock for a total price of $1,220,815 over the past three months.

At this time, corporate insiders control 5.50 percent of the company’s stock.

There have been several different brokerage firms that have produced reports on MLAB and made them public.

Evercore ISI stated they would increase their price target for Mesa Laboratories shares to $166.00 in a research note published on November 15th. The company Mesa Laboratories was given a recommendation of “sell” in a research report published on Saturday, January 21st, by StockNews.com. This recommendation is a downgrade from the company’s previous rating of “hold.”

Tags

Leave a comment

Your email address will not be published. Required fields are marked *